Therapeutic Advances in Musculoskeletal Disease

Therapeutic Advances in Musculoskeletal Disease is a gold open access journal from SAGE that was launched in 2009 and covers rheumatology, osteoporosis and related disciplines. It publishes reviews and original research, and its 2025 impact factor is 3.3.《肌肉骨骼疾病治疗进展》是 SAGE 出版的金色开放获取期刊，2009 年创办，覆盖风湿病学，骨质疏松症及相关学科。该刊发表综述与原创研究，2025 年影响因子为 3.3。

Scope

• The journal takes original research articles, reviews and scholarly comment on the treatment of musculoskeletal disease.该刊接收肌肉骨骼疾病治疗方面的原创研究论文，综述与学术评论。

• Rheumatology is a named subject, so work on inflammatory joint disease has a place in it.风湿病学是一个列出的主题，因此炎性关节病方面的工作在该刊有其位置。

• Osteoporosis is covered, and the loss of bone with age is studied beside its treatment.骨质疏松症也在覆盖之列，随年龄发生的骨丢失与治疗一并研究。

• Rheumatoid arthritis is named among the conditions, and a paper may report a trial of a new agent.类风湿关节炎被列为所涉疾病之一，论文可以报告一种新药的试验。

• Osteoarthritis appears on the list, so work on the degeneration of a joint is taken.骨关节炎出现在清单上，因此关节退变方面的工作会被接收。

• Psoriatic arthritis and ankylosing spondylitis are named as well, which brings the spondyloarthritides within reach.银屑病关节炎与强直性脊柱炎也被列出，这把脊柱关节炎类疾病纳入其中。

• The medical treatment of these conditions is the focus, and a drug is studied through its effect on the patient.这些疾病的药物治疗是重点，药物通过其对患者的作用受到研究。

• Reviews of an area are taken, since a reader may need the state of play gathered in one place.某领域的综述会被接收，因为读者可能需要在一处汇集的现状。

• Papers on how a treatment is delivered in practice are welcome.治疗在实践中如何实施方面的论文受到欢迎。

• Outcome measures and the way a benefit is judged are taken as subjects.结局指标与获益被评判的方式被当作选题接收。

• The journal takes work on the safety of a therapy, since a benefit is weighed against a risk.该刊接收疗法安全性方面的工作，因为获益是与风险相权衡的。

• The journal takes original research, reviews and scholarly comment, so a paper may report a trial or gather what is known of a therapy.该刊接收原创研究，综述与学术评论，因此论文可以报告一项试验，或汇集某一疗法的已知内容。

• It is aimed at clinicians and at researchers, and a review is written so that a busy reader can take the point from it.该刊面向临床医生与研究者，综述的写法使繁忙的读者能从中抓住要点。

• The journal covers the medical treatment of osteoporosis, and a paper may compare two agents that slow the loss of bone.该刊覆盖骨质疏松症的药物治疗，论文可以比较两种减缓骨丢失的药物。

• Rheumatoid arthritis is studied in its pages, and a report may set out how well a patient responds to a biologic.类风湿关节炎在其版面中得到研究，报告可以说明患者对某种生物制剂的应答程度。

• Spondyloarthritis is covered, so work on the axial and on the peripheral forms of the disease has a place.脊柱关节炎也在覆盖之列，因此对疾病的轴向型与周围型的研究有其位置。

• The journal takes work on psoriatic arthritis, since it overlaps with the skin disease and is managed across specialties.该刊接收银屑病关节炎方面的工作，因为它与皮肤病重叠并需跨专科管理。

• Gout and crystal arthritis appear among the subjects, and their management is studied beside the metabolic setting.痛风与晶体性关节炎出现在选题之中，其管理与代谢背景一并研究。

• The journal publishes work on pain, since relief is a large part of what a patient asks of a treatment.该刊发表疼痛方面的工作，因为缓解是患者对治疗的主要诉求之一。

• Papers on the safety of long-term therapy are taken, as a chronic disease is treated over many years.长期治疗的安全性论文会被接收，因为慢性疾病要治疗多年。

• The journal carries work on imaging and on the measurement of joint damage, which shows whether a treatment is holding a disease back.该刊载有影像与关节损伤测量方面的工作，它们显示治疗是否阻止了疾病。

• Data from registries are used, since a large group of patients shows effects that a trial is too small to catch.登记数据被使用，因为庞大的患者群显示出试验因规模太小而无法捕捉的效应。

• The journal takes papers on adherence, because a drug that is not taken cannot work.该刊接收依从性方面的论文，因为未被服用的药物无法起作用。

• Work on the cost and the organisation of care is welcome, since access shapes the benefit a treatment delivers.照护的成本与组织方面的工作受到欢迎，因为可及性塑造了治疗所带来获益。

• The journal publishes editorials that frame a debate, so a reader may see where the field is going.该刊发表框定一场争论的社论，因此读者可以看到领域走向何方。

• The journal takes work on the rehabilitation of a patient with joint disease, since treatment does not end with a prescription.该刊接收关节疾病患者康复方面的工作，因为治疗并不止于一张处方。

• A paper may study the link between a musculoskeletal condition and another disease.论文可以研究某一肌肉骨骼疾患与另一种疾病的联系。

• The journal covers the diagnosis of a rheumatic disease, and a report may compare two ways of arriving at it.该刊覆盖风湿病的诊断，报告可以比较达成诊断的两种方式。

• Work on the patient's own account of the disease is taken, since pain and function are reported by the person who has them.患者对疾病的自我报告方面的工作会被接收，因为疼痛与功能由患者本人报告。

• The journal publishes work on predictors of response, so a clinician may know who will benefit.该刊发表应答预测因素方面的工作，因此临床医生可以知道谁会获益。

• Papers on the epidemiology of a rheumatic disease appear, since the number of cases shapes the demand for care.风湿病的流行病学论文出现于该刊，因为病例数塑造了对照护的需求。

• The journal carries work on the education of patients, because a disease managed at home needs a patient who understands it.该刊载有患者教育方面的工作，因为在家管理的疾病需要一位理解它的患者。

• The journal takes work on exercise as a treatment for a rheumatic disease.该刊接收把运动作为风湿病治疗手段的工作。

• It publishes reports on how a drug performs outside a trial, in the ordinary clinic.该刊发表药物在试验之外，在日常门诊中表现如何的报告。

• The journal takes work on the imaging of a joint before and after a course of treatment.该刊接收疗程前后关节影像方面的工作。

History

• The journal was launched in 2009, and it has appeared every year since.该刊于 2009 年创办，此后逐年出版。

• It is published by SAGE, and it is among that house's gold open access titles.该刊由 SAGE 出版，属于该社的金色开放获取刊物。

• All articles are freely available online as soon as they are published.所有文章一经发表即可在线免费获取。

• The print number is 1759-720X and the electronic number 1759-7218.其印本刊号为 1759-720X，电子刊号为 1759-7218。

• A volume appears each year, so the journal is continuous rather than divided into numbered issues.该刊每年出版一卷，因此是连续出版而非分编号期。

• Its impact factor was 5.346 for 2021 and 3.3 for 2025, with a five-year figure of 4.0.其影响因子 2021 年为 5.346，2025 年为 3.3，五年影响因子为 4.0。

• The journal is listed in PubMed and indexed in the Science Citation Index Expanded.该刊被 PubMed 收录，并进入科学引文索引扩展版。

• Scopus and ProQuest carry it as well, so its papers are found through several services.Scopus 与 ProQuest 也载有该刊，因此其论文可经由多种服务找到。

• It is a member journal of the Committee on Publication Ethics.该刊是出版伦理委员会的成员期刊。

• Its articles are read more than three hundred thousand times in a year, as the publisher records.据出版方记录，其文章一年被阅读三十万次以上。

• Every paper is peer reviewed, and the publisher states that the review is rigorous.每篇论文都经同行评审，出版方声明评审是严格的。

• The title sits in a family of therapeutic advances journals that share a model.该刊属于一个共用同一模式的治疗进展期刊家族。

Editors

• (Denis Poddubnyy) is the editor of the journal.（Denis Poddubnyy）是该刊主编。

• The journal is edited for SAGE, and the editor works with a board of rheumatologists.该刊为 SAGE 编辑，主编与一个风湿病学编委会合作。

• The board covers the branches of musculoskeletal medicine that the journal publishes.编委会覆盖该刊所发表的肌肉骨骼医学各分支。

• A manuscript is sent to reviewers who work on the condition it concerns.稿件被送给研究其所涉疾病的评审人。

• The editors receive the reports and take the decision on a paper.编辑收到报告后就论文作出决定。

• The journal office answers queries about submission and follows each paper.该刊办公室答复关于投稿的询问并跟踪每篇论文。

• Because the title is open access, the review and the publication are managed so that a paper is free to all readers.由于该刊是开放获取的，评审与出版被安排为使论文对全体读者免费。

• The editors state that a study is judged on whether it changes what a clinician would do.编辑声明一项研究据其是否改变临床医生的做法来评判。